EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Sex differences in chemotherapy-induced neuropathic pain: mechanisms and pharmacotherapy

Xuewei Wu, Litao Chen, Yushan Chen, Yixin Liu, Xiaowei Chen iD

Journal of Pharmacy and Pharmacology · 05.03.2026 · 78 (3)

DOI: 10.1093/jpp/rgag025 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 25.03.2026. Verfasst von Xuewei Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Health Science Center, Ningbo University, 818 Fenghua Road, Ningbo, Zhejiang 315211, P. R. China. Hauptthemen laut MEDLINE: Neuralgia, Analgesics, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 141 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Ningbo Top Medical and Health Research Program, Ningbo Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and serious side effect of cancer treatment. Studies have shown that there is significant sexual dimorphism in animal models, molecular mechanisms and drug treatment responses of CIPN-related pain. This review systematically explores these sex differences in CIPN. Key findings Mechanistically, the pain sensitivity of female mice is mainly dependent on the IL-23/IL-17A/TRPV1 signaling axis, bidirectionally regulated by estrogen and its receptor α (ER-α). In contrast, male mice are more driven by TLR9-mediated macrophage activation and subsequent TNF/CXCL1 release. Pharmaco-therapeutically, both pre-clinical and clinical studies of duloxetine have shown that females may have better efficacy. The efficacy of κ-opioid receptor (KOR) agonist, resolvin D5 (RvD5), Mitragynine, sphingosine-1-phosphate receptor 1 (S1PR1) antagonist and adenosine A3 receptor (A3AR) agonist also varies by sex and type of chemotherapy drugs.

Conclusions

Sex is a crucial biological variable in CIPN, influencing drug efficacy through sex-specific neuroimmune mechanisms and hormonal regulation. These findings underscore the necessity of incorporating sex as a key variable in analgesic development and clinical practice to achieve personalized pain management in CIPN patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuralgiaAnalgesicsAntineoplastic AgentsAnimalsHumansFemaleMaleSex CharacteristicsSex Factors

Stichwörter der Autor:innen

CIPNanalgesiachemotherapysex differences

Substanzen

AnalgesicsAntineoplastic Agents

Autor:innen und Institutionen

  • Health Science Center, Ningbo University, 818 Fenghua Road, Ningbo, Zhejiang 315211, P. R. China.
  • Zhejiang Key Laboratory of Drug Addiction & Brain Health, The Affiliated Kangning Hospital of Ningbo University, 1 Zhuangyu South Road, Ningbo, Zhejiang 315211, P. R. China.

ORCID-Profile: Xiaowei Chen

Förderung

  • National Natural Science Foundation of China
  • Ningbo Top Medical and Health Research Program
  • Ningbo Natural Science Foundation

Zitieren

APA

Wu, X., Chen, L., Chen, Y., Liu, Y., & Chen, X. (2026). Sex differences in chemotherapy-induced neuropathic pain: mechanisms and pharmacotherapy. Journal of Pharmacy and Pharmacology, 78(3). https://doi.org/10.1093/jpp/rgag025

Vancouver

Wu X, Chen L, Chen Y, Liu Y, Chen X. Sex differences in chemotherapy-induced neuropathic pain: mechanisms and pharmacotherapy. Journal of Pharmacy and Pharmacology. 2026;78(3). doi:10.1093/jpp/rgag025

BibTeX
@article{Wu2026,
  author = {Wu, Xuewei and Chen, Litao and Chen, Yushan and Liu, Yixin and Chen, Xiaowei},
  title = {Sex differences in chemotherapy-induced neuropathic pain: mechanisms and pharmacotherapy},
  journal = {Journal of Pharmacy and Pharmacology},
  year = {2026},
  volume = {78},
  number = {3},
  doi = {10.1093/jpp/rgag025}
}
Kostenlos starten →